PGRN inhibits CD8+T cell recruitment and promotes breast cancer progression by up-regulating ICAM-1 on TAM
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03655-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Ting Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, 4…. Hauptthemen laut MEDLINE: Intercellular Adhesion Molecule-1, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing Municipality.
Abstract (Originalsprache)
Background
Tumor microenvironment actually reduces antitumor effect against the immune attack by exclusion of CD8 + T cells. Progranulin (PGRN) is a multifunctional growth factor with significant pathological effects in multiple tumors; however, its role in immunity evasion of breast cancer (BCa) is not completely understood.
Methods
We depleted GRN (PGRN gene) genetically in mice or specifically in PY8119 murine BCa cell line, and mouse models of orthotopic or subcutaneous transplantation were used. Chimeric mice-deficient of PGRN (Grn −/− ) in bone marrow (BM) compartment was also generated. Association of PGRN expression with chemokine production or BCa development was investigated by histological and immunological assays.
Results
We found PGRN was involved in exhaustion of cytotoxic CD8 + T cell in BCa with the increasing expressions of M2 markers and intercellular cell adhesion molecule-1 (ICAM-1) on macrophages. Specifically, ablation of PGRN in PY8119 cells reduced tumor burden, accompanied by the infiltrating of cytotoxic CD8 + T cells into tumor nests. Moreover, our result revealed that blockade of PD-1 in PGRN-depleted tumors exhibited better antitumor effect in vivo and significantly decreased tumor burden.
Conclusion
These findings suggest that inhibition of PGRN may act as a potential immune-therapeutic strategy by recovering infiltration of CD8 + T cell in BCa tissue and thereby enhancing the response to anti-PD-1 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, People's Republic of China.
- Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, People's Republic of China. chengsenchai@cqmu.edu.cn.
- Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, 400030, People's Republic of China. guo_bianqin@163.com.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Zhou, T., Qian, H., Zhang, D., Fang, W., Yao, M., Shi, H., Chen, T., Chai, C., & Guo, B. (2024). PGRN inhibits CD8+T cell recruitment and promotes breast cancer progression by up-regulating ICAM-1 on TAM. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03655-z
Vancouver
Zhou T, Qian H, Zhang D, Fang W, Yao M, Shi H, et al. PGRN inhibits CD8+T cell recruitment and promotes breast cancer progression by up-regulating ICAM-1 on TAM. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03655-z
BibTeX
@article{Zhou2024,
author = {Zhou, Ting and Qian, Husun and Zhang, Dian and Fang, Wenli and Yao, MengLi and Shi, He and Chen, Tingmei and Chai, Chengsen and Guo, Bianqin},
title = {PGRN inhibits CD8+T cell recruitment and promotes breast cancer progression by up-regulating ICAM-1 on TAM},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03655-z}
}
EUVIMED